Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...
Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
ROCKVILLE, MD – The Obesity Society (TOS) acknowledges the U.S. Food and Drug Administration's (FDA) recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and Ozempic; two ...
The pharma giant will now offer 7.5mg and 10mg dosages of Zepbound, as well as lower rates for its 2.5mg and 5mg vials.
Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...
More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
Supplies of high-demand obesity drugs are improving – but they’re not easier to get - ‘There are a lot of people right now ...
On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.
Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn’t ...